For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program.

In this market, the founders who succeed are generally the ones anchored by a strong “why,” a deep sense of humility, and a willingness to take their medicine when reality demands it.

Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging.

What do life sciences companies need to know about capital markets heading into 2026?

Congress is inching closer to passing the BIOSECURE Act and imposing restrictions on federal agencies and grant recipients related to biotechnology companies of concern.

The femtech sector's evolution presents opportunities for tech, healthcare, and life sciences companies that are both vast and largely...

In an unusual move, the U.S. Department of Justice and U.S. Patent and Trademark Office submitted a “Statement of Interest” this week in...

A break fee in a merger-gone-south can be deducted as an ordinary expense, the U.S. Tax Court held today, finding for biopharmaceutical...

As BIO 2025 approaches in Boston, eight pivotal trends are emerging at the intersection of science, business, IP, and regulation:...

I recently had the chance to contribute to a thoughtful and timely piece by my good friend and podcast co-host, Halle Tecco. After 15...